Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2014-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2014
2014-05-12 English
FORM 8-K FILING DOCUMENT
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated May 12, 2014, from MannKind Corporation. It specifically states in Item 2.02 that it is reporting financial results for the quarter ended March 31, 2014, and includes a press release as an exhibit. The document is a current report announcing quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document length is 3272 characters, which is relatively short and typical for an 8-K earnings announcement. It is not the full quarterly report (IR) but an initial announcement of quarterly financial results. Therefore, the correct classification is Earnings Release (ER).
2014-05-12 English
FORM 4 SUBMISSION
Director's Dealing
2014-04-25 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2014-04-11 English
FORM 8-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing, which is a current report filed with the SEC to announce specific events or updates. The content includes an announcement about the FDA extending the PDUFA date for a drug, and it references an attached press release. The document is short (2750 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed regulatory compliance information beyond the event announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2014-04-07 English
FORM 8-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated April 1, 2014. It reports an event related to the FDA advisory committee's recommendation for drug approval, which is a significant corporate event but not a financial report or earnings release. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. The length is 3263 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a material event (FDA advisory committee recommendation) and does not fit other more specific categories like earnings release or annual report.
2014-04-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.